Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93706 | 0.82 | RELA (0.47) | RELAMEN1KMT2ANR1I2TP53 | |
| SCHEMBL9798232 | 0.82 | ALDH1A1 (0.39) | RELAALDH1A1TSHRKDM4EHPGD | |
| SCHEMBL8340935 | 0.82 | RELA (0.40) | RELAMEN1KMT2ANR1I2TP53 | |
| SCHEMBL8341640 | 0.80 | RELA (0.39) | RELAMEN1KMT2ANR1I2TP53 | |
| SCHEMBL6672654 | 0.79 | TSHR (0.56) | TSHRKDM4EPOLBMAOAMAOB | |
| SCHEMBL5410674 | 0.78 | TRPA1 (0.39) | RELAMEN1KMT2ATP53ALDH1A1 | |
| SCHEMBL815747 | 0.74 | MEN1 (0.39) | RELAMEN1KMT2ANR1I2TP53 | |
| SCHEMBL425560 | 0.71 | TSHR (0.50) | ALDH1A1TSHRKDM4EMAOAMAOB | |
| SCHEMBL317685 | 0.71 | LTA4H (0.47) | RELAMEN1KMT2ATP53ALDH1A1 | |
| SCHEMBL28054696 | 0.71 | RELA (0.41) | RELAKMT2ATP53ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809822-B2 | Triptolide derivatives and preparation method and use thereof | HONG KONG BAPTIST UNIVERSITY (HK) | 2017-11-07 | — | — | US | claimed |
| US-20160362691-A1 | TRIPTOLIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF | HONG KONG BAPTIST UNIVERSITY (HK) | 2016-12-15 | — | — | US | claimed |
| US-9809822-B2 | Triptolide derivatives and preparation method and use thereof | HONG KONG BAPTIST UNIVERSITY (HK) | 2017-11-07 | — | — | US | disclosed |
| US-20160362691-A1 | TRIPTOLIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF | HONG KONG BAPTIST UNIVERSITY (HK) | 2016-12-15 | — | — | US | disclosed |
| US-20130267680-A1 | TOTAL CHEMICAL SYNTHESIS OF UBIQUITIN, UBIQUITIN MUTANTS AND DERIVATIVES THEREOF | STICHTING HET NEDERLANDS KANKERINSTITUUT | 2013-10-10 | — | — | US | disclosed |
| EP-2616479-A1 | TOTAL CHEMICAL SYNTHESIS OF UBIQUITIN, UBIQUITIN MUTANTS AND DERIVATIVES THEREOF | Stichting Het Nederlands Kanker Instituut (NL) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012036551-A1 | TOTAL CHEMICAL SYNTHESIS OF UBIQUITIN, UBIQUITIN MUTANTS AND DERIVATIVES THEREOF | STICHTING HET NEDERLANDS KANKERINSTITUUT (NL) | 2012-03-22 | — | — | WO | disclosed |
| US-5952504-A | REACTING A SULFONATED, HALOGENATED OR PHOSPHONATED 1,7-NAPHTHYRIDINE COMPOUNDS WITH AN AROMATIC AMINE DERIVATIVE; ANTIULCER AGENT | YUNGJIN PHARMACEUTICAL COMPANY, LTD. (KR) | 1999-09-14 | — | — | US | disclosed |
| EP-0843677-A1 | 4-AMINO-3-ACYLNAPHTHYRIDINE DERIVATIVES | YUNGJIN PHARMACEUTICAL CO., LTD. (KR) | 1998-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267680-A1 | TOTAL CHEMICAL SYNTHESIS OF UBIQUITIN, UBIQUITIN MUTANTS AND DERIVATIVES THEREOF | UBQLN1, UBQLN2, UBE3A | RELA 953/4885MEN1 2901/4885KMT2A 498/4885 |
| US-20160362691-A1 | TRIPTOLIDE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF | TPD52L2, TRDMT1, MCTS1 | RELA 1518/4885MEN1 1435/4885KMT2A 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.